Syantra Inc. is a privately held company focused on the commercialization of their breast cancer detection blood test, Syantra DX | Breast Cancer. With over five years of research, development, and validation through retrospective data, Syantra DX | Breast Cancer has shown to provide definitive, rapid, and efficient detection of breast cancer from a patient blood sample.
In order to validate the test for regulatory and clinical approval, the company is currently conducting clinical studies in various locations in Canada, the United Kingdom and the United States. Syantra will soon begin a clinical study in South Korea. Syantra will be updating this website with information on the progress and results for each of these investigations.